Evaluation and Validation of the Limited Sampling Strategy of Polymyxin B in Patients with Multidrug-Resistant Gram-Negative Infection.

ABSTRACT: Polymyxin B (PMB) is the final option for treating multidrug-resistant Gram-negative bacterial infections. The acceptable pharmacokinetic/pharmacodynamic target is an area under the concentration-time curve across 24 h at a steady state (AUC_ss,24h) of 50-100 mg·h/L. The limited sampling strategy (LSS) is useful for predicting AUC values. However, establishing an LSS is a time-consuming process requiring a relatively dense sampling of patients. Further, given the variability among different centers, the predictability of LSSs is frequently questioned when it is extrapolated to other clinical centers. Currently, limited data are available on a reliable PMB LSS for estimating AUC_ss,24h. This study assessed and validated the practicability of LSSs established in the liter

SUBMITTER: Li X 

PROVIDER: S-EPMC9698835 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature